Ph2 resultsThe way I look at it is to date we have had 3 patients treated at the full dosage in Ph1. 1 was dropped likely due to undiagnosed metatastic cancer. However they still count so we sit at 2 out of 3 for success being cancer free for over 18 months.
As often happens with trials for new treatments larger numbers treated could reduce the efficacy rate shown in Ph 1. That is why I think that we sit at the low price we do. We just have not had the numbers treated yet to prove out the efficacy rate.... that and the fact we have a fair amount of outstanding shares.
I am hanging onto my shares and will wait for the story to unfold with Ph2 results. As far as I know, we currently have only 2 enrolled in this Ph2 study. So I suspect the 6 month results for a more significant number of patients won't be seen until the second half of 2020 and mid to late 2021 for 6 months (or more) results for all enrolled.
Having had a cousin die of bladder cancer, I hope that the efficacy rate for TLT's treatment will be high. And if it is, I find it impossible to assess what the future share price of TLT will be if this treatment shows a high percentage of successful results. What would we sit at when favorable results were released on a large number of Ph 2 patients? $1.50? $10?